linjc16/ctgov huggingface dataset:
Gripwise® Versus JAMAR®

Study Overview
=================
Brief Summary
-----------------
It is recommended to screen ageing patients for sarcopenia, due to the increased risk of morbimortality if detected positive. According to the consensus of the European Working Group on Sarcopenia in Older People, the diagnosis of sarcopenia is based, among other things, on grip strength measurement. Our study will compare the performance of the new GRIPWISE digital device with the mechanical dynamometer JAMAR, the gold standard currently used to assess the grip strength. We propose to evaluate it in an elderly hospitalized population where the prevalence of sarcopenia is likely to be high due to the high prevalence of various chronic illness, notably oncological and cardiological ones. This cross-sectional study will include 348 patients.

Official Title
-----------------
Comparison of Gripstrength Assessment Between the Gripwise® and JAMAR® Dynamometers in Elderly Inpatients

Conditions
-----------------
Age-Related Sarcopenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men and women aged 65 or over affiliated to a health insurance Francophone. Exclusion Criteria: - refusal to participate unable to communicate unable to use both hands (dominant and non-dominant)

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| single group<br>gripwise or jamar will be randomly assessed first | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison between Jamar® and Gripwise® values for grip strength measurement | Intra-class correlation between the best values obtained with each device | day1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparison according to the patient's position | correlations of dynamometer measurements between patients assessed in the sitting or lying position | day1 | 
| number of attempt to reach the maximum value | Comparison of the three measurements obtained for each patient with each device | day1 | 
| factors influencing detected weakness | significant difference in the rate of women detected as weak with a handgrip <16kg and men <27kg, between the different reasons for hospitalisation, the number of days of hospitalisation, and between the different chronic cancerous and non-cancerous pathologies (Updated Charlson Comorbidity Index), the age groups 65-79 years and ≥80 years | day1 | 
| satisfaction using the devices | rate of patients finding one of both device easier to use | day1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aged, inpatients, hand strength
Knowledge Base in the Treatment of Atopic Dermatitis Among Thai Pediatricians

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine knowledge base in diagnosis, investigation and treatment of pediatric atopic dermatitis among thai pediatricians.

Detailed Description
-----------------
Background: Currently, there is no existing information regarding prescribing practices for the management of childhood atopic dermatitis among pediatricians in Thailand. Objective: In order to learn about basic knowledge, natural history, evaluation, diagnosis, treatment and prevention for childhood atopic dermatitis in Thailand Methods: 900 self-administered questionnaires were randomly mailed to pediatricians throughout Thailand, asking about their preferences in the management of childhood atopic dermatitis. One hundred and eighty-five of these 900 questionnaires were returned (a response rate of 20.6%)

Conditions
-----------------
Childhood Atopic Dermatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All pediatricians who're working in thailand including sub-board pediatricians.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atopic dermatitis, Thai pediatricians
Measuring the Incidence of Hospital Readmissions Based on Adverse Drug Events

Study Overview
=================
Brief Summary
-----------------
An ADE is defined as harm caused by a drug or the inappropriate use of a drug. Retrospective record reviews in several countries have shown that anticoagulants frequently lead to hospital readmissions. In this study a hospital readmission is defined as an admission to the emergency department of the Jessa hospital. The objective of this study is to determine the incidence of one week and 30-day readmissions caused by (preventable) ADE's due to anticoagulants.

Official Title
-----------------
Measuring the Incidence of Hospital Readmissions, Caused by Adverse Drug Events (ADE) Due to Anticoagulants in Vzw Jessa Hospital (Belgium)

Conditions
-----------------
Incidence of Readmissions, ADE's Due to Anticoagulants

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who received an anticoagulant on their last day of admission Patients who were readmitted within 30 days Patients who were diagnosed using the pathology registration of the emergency department of the Jessa hospital Exclusion Criteria: Patients who didn't receive an anticoagulant on their last day of admission Patients who were not readmitted within 30 days Patients who were not diagnosed using the pathology registration of the emergency department of the Jessa hospital Patients with missing data
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of readmissions within one week caused by ADE's due to anticoagulants |  | up to one week | 
| incidence of readmissions within 30 days caused by ADE's due to anticoagulants |  | up to 1 month | 
| incidence of preventable ADE's leading to readmission |  | week 1, month 1 |
Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Hemostasis in Subjects Undergoing Total Hip Replacement

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to monitor the safety of FS VH S/D and evaluate whether FS VH S/D is superior to standard treatment in reducing blood loss in subjects undergoing total hip replacement with cement-free hip prostheses.

Official Title
-----------------
A Randomized, Controlled, Multicenter Study to Evaluate Efficacy and Safety of Fibrin Sealant VH S/D for Hemostasis in Subjects Undergoing Total Hip Replacement

Conditions
-----------------
Hip Replacement Surgery

Intervention / Treatment
-----------------
* Drug: Fibrin Sealant Vapor-Heated Solvent/Detergent-treated


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Each subject to be included into the study must fulfill the following inclusion criteria: Subjects receiving a cement free hip prosthesis due to coxarthrosis because of primary or dysplastic arthrosis grade 1 - 3 according to Crowe or rheumatoid arthritis as well as subjects receiving a cement free hip prosthesis due to femur head necrosis (Crowe classification). ASA and NSAIDs have been discontinued one week prior to surgery Written informed consent Male and female at least 19 years of age Exclusion Criteria: Subjects fulfilling the following exclusion criteria will not be recruited into the study: Impaired coagulation Previous hip surgery Acetabular roof plastic Known hypersensitivity to aprotinin or other components of the product Immunodeficiency Increased red cell production Pregnant or lactating women (positive urine or serum pregnancy test; this test is required of any female subject who is not post menopausal or surgically sterilized). Subjects concurrently participating in another clinical trial or having received another investigational drug within the last 30 days. Also patients with abnormal coagulation values due to anticoagulants like coumadins or heparin must be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arthroplasty, Hip Prosthesis, Cement Free Hip Prosthesis, Femur Head Necrosis, Coxarthrosis
Comparison of Image Quality Between New Collimator LEHRS vs Siemens LEHR on Bone Scintigraphy

Study Overview
=================
Brief Summary
-----------------
Comparison of quality image with a new LEHRS GE collimator vs standard LEHR Siemens collimator on bone scintigraphy.

Official Title
-----------------
Comparison of Image Quality Between New Collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on Bone Scintigraphy

Conditions
-----------------
Comparison of Two Collimators During Bone Scintigraphy

Intervention / Treatment
-----------------
* Other: Bone scintigraphy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Refered patients for scintigraphy Exclusion Criteria: Under 18 y. old patients Pregnancy or supposed to be pregnant patients Kidney failure Painful patients Patients under guardianship Patients in whom a standard exam is not feasible

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Refered patients for scintigraphy<br> | Other: Bone scintigraphy<br>* Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual quality of bone exams |  | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative signal-noise-ratios |  | Day 0 | 
| quantitative datas on phantom |  | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
collimator, bone scintigraphy, image quality, scintigraphy
The Influence of Cortical Bone Perforation on Guided Bone Regeneration in Humans

Study Overview
=================
Brief Summary
-----------------
The purpose of this randomized clinical trial was to evaluate the effect of cortical bone decortication on the angiogenesis and osteogenesis of augmented ridge by GBR.

Detailed Description
-----------------
Background: The purpose of the current study was to evaluate the effect of cortical bone perforation on angiogenesis and osteogenesis of augmented ridge by guided bone regeneration. Methods: Fourteen patients (mean age: 52) who were in need of dental implants at areas with osseous defects in the mandible were selected. In the test group (n=7), alveolar cortical bone at the area of regeneration was perforated using a #2 high speed round bur. No decortication of cortical bone was performed in the control group (n=7). Subsequently, defects were augmented by guided bone regeneration using resorbable membrane and bovine bone. After a healing period of 7 months, implant sites were created and trephine cores harvested for histological and histomorphometric analysis of the grafted areas.

Official Title
-----------------
The Influence of Cortical Bone Perforation on Guided Bone Regeneration in Humans: A Randomized Clinical Trial

Conditions
-----------------
Alveolar Bone Loss

Intervention / Treatment
-----------------
* Procedure: Decortication


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion criteria were presence of atrophic mandibular ridges with bucco-lingual width ranging between 2-5 mm, as measured on serial sections of a computerized axial tomography (CAT) scan. Exclusion Criteria: Exclusion criteria included patients with diabetes, osteoporosis or other metabolic disorders, smokers, pregnant patients and patients who had any systemic or local factors that would inhibit normal wound healing process.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: test group<br>decortication group | Procedure: Decortication<br>* cortical bone perforation<br>|
| No Intervention: control<br>without decortication | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The amount of vital bone formation by histomorphometric analysis after cortical bone perforation |  | 7 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
histomorphometry
Imaging Lens Deposits in Exfoliation Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to use a special eye imaging technique, anterior segment optical coherence tomography (AS-OCT), to image the lens (the curved, transparent part of the eye that helps you to see clearly by directing images of light onto the back of your eye) and note any changes in exfoliation syndrome. Exfoliation syndrome is a common condition that has many ways of showing up in the eye, including the formation of deposits in the eye, shakiness of the lens that can complicate cataract surgery, and a higher chance of developing a type of glaucoma called exfoliation glaucoma. In this study we plan to collect images and measure exfoliation deposits on the lens with AS-OCT, which can take high resolution pictures of the eye without requiring contact with the eye. We will compare lens images of subjects with exfoliation syndrome to those of subjects with primary open angle glaucoma and cataracts. This type of imaging could be used in patients with known diagnosis of exfoliation syndrome to track disease progression and see how they respond to possible treatments. We also hope that with this imaging technology we can detect early changes in currently unaffected eyes, which could be useful for predicting which patients may develop the disease.

Official Title
-----------------
Imaging Lens Changes in Exfoliation Syndrome Using Anterior Segment OCT

Conditions
-----------------
Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts

Intervention / Treatment
-----------------
* Device: anterior segment OCT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of exfoliation syndrome, primary open angle glaucoma (POAG), or cataracts Exclusion Criteria: Unable to provide or sign consent Pseudophakia Other prior intraocular surgery Other eye diseases other than refractive error

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| exfoliation syndrome<br>patients with exfoliation syndrome | Device: anterior segment OCT<br> <br> |
| POAG<br>patients with primary open angle glaucoma (POAG) | Device: anterior segment OCT<br> <br> |
| cataracts<br>patients with cataracts | Device: anterior segment OCT<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of exfoliation deposits on the lens as measured by AS-OCT |  | 20 min (length of imaging) |
The Efficacy and Safety of a Novel Adjunctive Pacing Strategy During Rotational Atherectomy

Study Overview
=================
Brief Summary
-----------------
Coronary artery narrowings interfere with blood flow to the heart which can cause chest pain and heart attacks. Cardiologists can treat these narrowings with balloons and stents. However, some narrowings can become very calcified and hard making treatment with balloons and stents difficult. Rotational atherectomy is a tool to treat calcific coronary disease. It uses an ablative drill to break down the hardened plaques inside the coronary arteries facilitating subsequent treatment with balloons and stents. However, during this procedure patients can experience a slow heart rate which may compromise procedural safety. Cardiologists may use a temporary pacemaker that is inserted by separately accessing the heart through a large vein usually from the leg. This maintains a safe heart rate throughout the procedure. However, inserting the temporary pacemaker is associated with additional complications. We have developed and propose an alternative strategy to provide a temporary safety pacemaker during rotational atherectomy without the need for inserting an additional pacemaker.

Official Title
-----------------
Strategy to ROTAblate and PACE (ROTA-PACE) Study

Conditions
-----------------
Coronary Artery Disease, Coronary Artery Calcification, Bradycardia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-90 years Undergoing percutaneous coronary intervention for angina or acute coronary syndrome. Calcific coronary disease requiring rotational atherectomy Exclusion Criteria: Pre-existing pacemaker or implantable cardioverter defibrillator. Mobitz II heart block or complete heart block.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful ventricular pacing | Ability to obtain successful ventricular capture prior to rotational atherectomy | At the start of the PCI procedure immediately prior to rotational atherectomy | 
| Ventricular pacing threshold | The pacing threshold to obtain successful ventricular capture | At the start of the PCI procedure immediately prior to rotational atherectomy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications | (a) Coronary wire-related intractable spasm (unresponsive to vasodilator therapy); (b) coronary wire-related perforation; (c) New atrial or ventricular arrhythmia | At the end of the PCI procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary Artery Calcification, Rotational Atherectomy, Temporary Pacemaker
Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan

Study Overview
=================
Brief Summary
-----------------
The study will evaluate the safety and efficacy of Patupilone in adult patients with advanced solid tumors.

Official Title
-----------------
A Phase IA, Open-label, Dose Escalation Study of Patupilone Administered Intravenously Every 3 Weeks in Adult Patients With Advanced Solid Tumors

Conditions
-----------------
Tumors

Intervention / Treatment
-----------------
* Drug: Patupilone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients with a histologically/cytologically confirmed diagnosis of advanced solid tumors refractory to or unsuitable for standard therapy, or for whom no standard therapy exists Patients with WHO Performance Status of 0-1 ( Karnofsky Performance Status of 80-100) At least one measurable lesion Exclusion criteria: Patients with any peripheral neuropathy Patients with unresolved diarrhea Patients with severe and/or uncontrolled medical conditions or infections that require systemic therapy Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EPO906<br> | Drug: Patupilone<br> <br> * Other names: EPO906;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose-limiting Toxicity |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of patupilone assessed by CTCAE |  | 18 months | 
| Pharmacokinetic profile of patupilone |  | 18 months | 
| Anti-tumor activity of patupilone according to the RECIST guidelines |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced solid tumor, Patupilone